Table 2.
Five-year progression- and event-free survival according to prognostic scoring systems in the training and validation cohorts
| Training cohort (PRIMA) | Validation cohort (FL2000+MER) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FLIPI | PRIMA-PI | FLIPI2 | β2m+LDH | FLIPI | PRIMA-PI | β2m+LDH | ||||||||
| N (%) | 5-y PFS % (95% CI) | N (%) | 5-y PFS % (95% CI) | N (%) | 5-y PFS % (95% CI) | N (%) | 5-y PFS % (95% CI) | N (%) | 5-y EFS % (95% CI) | N (%) | 5-y EFS % (95% CI) | N (%) | 5-y EFS % (95% CI) | |
| Low | 238 (21) | 68 (62-74) | 352 (34) | 69 (64-73) | 74 (6) | 75 (63-83) | 335 (32) | 65 (60-70) | 126 (28) | 76 (66-83) | 168 (36) | 77 (69-83) | 230 (52) | 69 (62-75) |
| Intermediate | 405 (36) | 58 (53-62) | 346 (34) | 55 (49-60) | 619 (55) | 60 (56-63) | 484 (46) | 51 (47-56) | 159 (35) | 64 (55-72) | 136 (29) | 57 (48-66) | 144 (32) | 51 (42-60) |
| High | 487 (43) | 44 (38-48) | 327 (32) | 37 (32-42) | 442 (39) | 41 (36-46) | 230 (22) | 41 (34-47) | 165 (37) | 45 (37-53) | 158 (34) | 44 (35-52) | 71 (16) | 44 (31-56) |